Long-term Safety Study of HRS-1893 Tablets in Adults with Hypertrophic Cardiomyopathy

What this Trial Is About

Researchers are evaluating the long-term safety of HRS-1893 in people with hypertrophic cardiomyopathy, a condition affecting the heart muscle. This phase 2 clinical trial focuses on monitoring potential side effects and heart function changes over time. The study is sponsored by Shandong Suncadia Medicine Co., Ltd. and aims to provide important information about how this medication affects heart health in this population. Participants receive the study drug HRS-1893 in tablet form. The trial includes two groups one for obstructive hypertrophic cardiomyopathy and one for non-obstructive hypertrophic cardiomyopathy. This is an open-label, non-randomized study where all participants receive the medication. The treatment period and follow-up involve regular assessments to monitor safety and heart function. During the study, participants will undergo evaluations including tracking adverse events and monitoring heart function through left ventricular ejection fraction measurements over about one year. Additional tests include measuring cardiac biomarkers like troponin and NT-proBNP at 24 and 52 weeks. Participants will also be monitored for compliance and safety throughout the study, which lasts approximately one year, with the last data collection expected by December 2027.

A Clinical Study to Evaluate the Long-term Safety of HRS-1893 in Hypertrophic Cardiomyopathy